Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression

Acta Pharmacologica Sinica

Volumn 30, Issue 8, 2009, Pages 1162-1168

  Wu, Kai Jie ^a   Zeng, Jin ^a   Zhu, Guo Dong ^a   Zhang, Lin Lin ^a   Zhang, Dong ^a   Li, Lei ^a   Fan, Jin Hai ^a   Wang, Xin Yang ^b   He, Da Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Invasion; Migration; MMP 2; Motility; Prostate cancer; Silibinin; Vimentin

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; SILIBININ; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTIOXIDANTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; SILYMARIN; VIMENTIN;

EID: 68349113541     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.94     Document Type: Article

References (26)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
3. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780
4. Singh RP, Agarwal R. Prostate cancer prevention by Silibinin. Curr Cancer Drug Targets 2004; 4: 1-11.
5. Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther 2002; 1: 525-532
6. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC-3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006; 25: 1053-1069 (Pubitemid 43277013)
7. Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998; 58: 1920-1929 (Pubitemid 28217468)
8. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 2007; 28: 2567-2574
9. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62: 3063-3069 (Pubitemid 34602396)
10. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007; 67: 11083-11091 (Pubitemid 350145939)
11. Mokhtari MJ, Motamed N, Shokrgozar MA. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int 2008; 32: 888-892
12. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008; 14: 7773-7780
13. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
14. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, et al. Microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006; 66: 1664-1673
15. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629-4637
16. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinogen 2004; 40: 143-149
17. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res 2006; 85: 220-225
18. Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem-Biol Interact 2005; 156: 141-150
19. Hsieh YS, Chu SC , Yang SF, Chen PN, Liu YC, Lu KH. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 2007; 28: 977-987
20. Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 2007; 354: 165-171
21. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial to mesenchymal transition in human breast cancer: observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203. (Pubitemid 46957486)
22. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26: 571-577
23. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, et al. Enhanced expression of Vimentin in motile prostate cancer cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002; 52: 253-263 (Pubitemid 34898891)
24. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149 (Pubitemid 30123793)
25. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270 (Pubitemid 27371946)
26. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry 2002; 67: 92-98